Impact of routine prophylaxis with monoclonal antibodies and maternal immunisation to prevent respiratory syncytial virus hospitalisations, Lombardy region, Italy, 2024/25 season

Background Respiratory syncytial virus (RSV) is a leading cause of hospitalisation in children worldwide. Recent regulatory approval of monoclonal antibody (mAb) nirsevimab for infants and the RSVpreF vaccine for pregnant women offers promising approaches to mitigate RSV-associated morbidity. Aim To...

Ful tanımlama

Detaylı Bibliyografya

Yazar:	Piero Poletti
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	European Centre for Disease Prevention and Control 2025-04-01
Seri Bilgileri:	Eurosurveillance
Konular:	maternally-acquired immunity transmission model respiratory syncytial virus monoclonal antibodies immunization programs respiratory syncytial virus vaccines
Online Erişim:	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.14.2400637
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!